scarletred
Home
Company
Products
Scarletred
®Vision
Scarletred
®Telemedicine
Services
Applications
News
Contact
Menu
01
Home
02
Company
03
Products
04
Services
05
Applications
06
News
07
Contact
Get in touch
Austria
SCARLETRED Holding GmbH
MQM 3.4, Maria Jacobi Gasse 1,
8th floor, 1030 Vienna, Austria
USA
SCARLETRED Inc.
1 Broadway, 14th floor,
Cambridge, MA 02142, USA
office@scarletred.com
Privacy Policy
Social
Linkedin
Linkedin
Linkedin
Twitter
Instagram
Instagram
Facebook
Facebook
info
Press
Career
FAQ
Regulatory
Imprint
News
Keywords:
#
Conferences
#
Skin Care
#
AAD 2023
#
BioJapan2022
#
JAK inhibitors
#
Safety monitoring
#
GlobalFemaleLeaders
#
GFL
#
EWMD
#
Arab Health 2022
News
•
Sep 27, 2023
Scarletred presents study at the 32nd EADV Congress in Berlin
SCARLETRED is presenting the results of their latest publication at the 32nd EADV Congress in Berlin, Germany. The study examined the use of deep learning algorithms for erythema scoring in radiation-induced dermatitis.
News
•
Aug 21, 2023
7th Dermatology Drug Development Summit in Boston: Scarletred Joins as Lead & Hosting Partner and Expert Speaker
The 7th Dermatology Drug Development Summit in Boston, USA, for inflammatory skin diseases presents novel therapeutics for rare and common skin diseases such as Atopic Dermatitis, Hidradenitis suppurativa, and more.
News
•
Aug 8, 2023
Join and Benefit From SCARLETRED’s Market Research Study for Telemedicine Applications in Atopic Dermatitis
Striving to develop and expand Scarletred®Vision’s telemedicine applications, we are happy to invite medical doctors to join our Discovery Program to include our software in clinical routine procedures free of cost.
News
•
Aug 6, 2023
President of the European Patent Office Mariana Karepova Talks about SCARLETRED Being Her Favorite Innovation in The Last Years
President of the European Patent Office Mariana Karepova shares her insights into the world of innovations and ideas while being president at the Austrian patent office and Scarletred being her favorite one in the last years.
News
•
May 30, 2023
Choosing the Right Sunscreen for Your Skin Type Can Prevent Sun-Induced Skin Damage: Scarletred Expands its AI-Powered Consultation Service at Seestadt Apotheke in Vienna
Scarletred cooperates with the Seestadt Apotheke to provide customers AI-based personalized skin care consultations and further education about preventing skin diseases, cancer, and ageing caused by exposure to UV rays.
News
•
Mar 22, 2023
New Publication using Scarletred®Vision to Show Positive Effects of Photobiomodulation on Wound Healing Processes
The study uses photobiomodulation at different wavelengths for wound care in diabetic wounds and resulted in signficant positive effects objectively shown by the medical device software Scarletred®Vision.
News
•
Mar 2, 2023
CEO Harald Schnidar in the B&C Group podcast about protection for innovations and patent rights
In the B&C Group's podcast Über:Mut, Scarletred's CEO Harald Schnidar discusses together with Mariana Karepova, President of the Austrian Patent Office, the protection and potential of innovations in Austria.
News
•
Feb 27, 2023
Dermatology Drug Development Summit 2023 Hosts Scarletred as Expert Partner
Scarletred’s CEO Harald Schnidar joins the Dermatology Drug Development Summit 2023 Europe in Berlin, Germany, to speak on the topic of AI-assisted objective skin imaging and analysis.
News
•
Feb 26, 2023
New Study Shows Meaningful Results with Bimiralisib in Mycosis Fungoides Patients using Scarletred®Vision
Topical Bimiralisib, used in patients with the rare cutaneous form of T-cell lymphoma, known as Mycosis fungoides, and healthy patients, showed substantial results regarding cutaneous drug levels.
News
•
Feb 20, 2023
SCARLETRED Joins 2023 AAD Annual Meeting in New Orleans, LA, USA
Our CEO Harald Schnidar is invited to present the results of a cooperation with GALDERMA and the University of Tübingen, wherein Scarletred®Vision confirmed the therapeutic efficacy of Ivermectin in Rosacea patients.
News
•
Nov 27, 2022
New Publication: Ivermectin Treatment in Rosacea
Discover our newest publication about Ivermectin treatment in rosacea patients in cooperation with the university clinic Tübingen, Germany, and how Scarletred®Vision helped monitor signs and symptoms.
News
•
Nov 26, 2022
Besuche SCARLETRED am kosmetischen Beratungstag in der Seestadt Apotheke
Die Seestadt Apotheke in 1220, Wien, lädt zu ihrem kosmetischen Beratungstag am 29.11.2022 ein. Unterstützt durch Produkte von Eucerin, wird Scarletred exklusiv helfen den Hautzustand zu erfassen und analysieren.
News
•
Oct 18, 2022
SCARLETRED Presenting at the 6th Dermatology Drug Development Summit in Boston
The 6th Dermatology Drug Development Summit for inflammatory skin diseases gives insight into novel therapeutics and patient-specific and alternative treatment options currently in clinical trials for various skin diseases.
News
•
Oct 5, 2022
BioJapan 2022: SCARLETRED Joins Innovative Companies at the Leading Life Science and Pharmaceutical Fair in Tokyo
The life science and pharmaceutical fair takes place October 11-14th to bring together innovative companies, customers, and investors. SCARLETRED is one of nine companies representing the Austrian Economic Chambers in Tokyo.
News
•
Sep 14, 2022
Presentation of data from our published paper “The mathematics of erythema” at the ÖGRO congress in Villach, Austria
Our published paper about machine learning and developing the SEV value will be presented at the ÖGRO annual congress in Villach, Austria, with our collaborator at the Landeskrankenhaus Graz, Dr. Richard Partl.
News
•
Sep 6, 2022
SCARLETRED at the 51st Annual ESDR Meeting
SCARLETRED is visiting and presenting at this year´s 51st Annual ESDR Summit taking place in Amsterdam, Netherlands between 28th September - 1st October 2022.
News
•
Aug 23, 2022
SCARLETRED Presents Results of a New Rosacea Study at the 31st EADV Congress in Milan, Italy
SCARLETRED visits the hybrid EADV congress in Milan from September 7-9, 2022, to present the results of a new rosacea study that used Scarletred®Vision to measure the effectiveness of a new treatment.
News
•
May 9, 2022
Scarletred®Vision system now approved as CE Class Im Medical Device
We are excited to announce that SCARLETRED has received a new EC declaration of conformity approving Scarletred®Vision as a physiological measuring system and a CE Class 1m medical device.
News
•
May 6, 2022
SCARLETRED's CFO at the Think Tank discussion at the Global Female Leaders Summit 2022
After 3 years, the well-renowned women's conference, Global Female Leaders Summit, will take place from the 8th-10th of May 2022 at the Adlon Hotel Kempinski in Berlin, Germany.
News
•
Mar 21, 2022
Benefits of Using Scarletred®Vision for Phase IV Post-Marketing Studies
Post-Marketing Studies play an integral role in gathering information about safety and efficacy on a large scale. However, monitoring adverse events and patient-reported outcomes in a real-world setting can be challenging.
News
•
Mar 7, 2022
New Diagnostic Accuracy Study Assessing SARS-CoV-2 Rapid Antigen Detection Tests using Scarletred®Vision
A study, performed by the Medical University of Vienna, examined diagnostic accuracy of SARS-CoV-2 rapid antigen tests compared to RT-PCR as the gold standard based on different swab sites by using Scarletred®Vision.
News
•
Mar 1, 2022
Meet SCARLETRED at the 3rd Dermatology Drug Development Europe Summit
Following a successful launch in Europe in 2019, and a tremendous online experience in 2021, the 3rd Dermatology Drug Development Europe Summit, returns in April 2022 in Frankfurt, Germany.
News
•
Feb 28, 2022
SCARLETRED Discovery Program (DP): SaaS as our novel flagship service for industry clinical trials
The DP aims to collaborate with pharmaceutical and biotechnology companies by providing access to our customizable software Scarletred®Vision for exploratory or early-stage clinical studies at a more attractive price point.
News
•
Jan 21, 2022
Arab Health 2022 exhibits SCARLETRED at its Global Healthcare Event
SCARLETRED is currently featured at the Arab Health 2022 exhibition in Dubai, among other companies in medical and healthcare-related categories. The networking event helps to connect and support innovations in healthcare.
News
•
Jan 21, 2022
Visit SCARLETRED at the EXPO 2020 - Connecting Minds, Creating the Future
The EXPO 2020 “Connecting Minds, Creating the Future” theme addresses visions of a networked and technology-based future. SCARLETRED is currently exhibited in the iLab section representing the future of digital healthcare.
News
•
Dec 14, 2021
SCARLETRED's digital solution for vaccine development featured in the business magazine “Gewinn”
The business magazine Gewinn discusses how Scarletred®Vision is an excellent addition to the safety and monitoring of injection site reactions (ISRs) in vaccine development.
News
•
Dec 13, 2021
Scarletred®Vision wins the Top Health Solution of the IÖB Call 2021
The national platform IÖB (public procurement promoting innovation) announced Austria’s top innovations. This year, the IÖB awarded SCARLETRED with Scarletred®Vision as a digital healthcare management solution.
News
•
Nov 17, 2021
SCARLETRED’s eHealth milestones featured in Austrian Newspaper “Der Standard”
The popular newspaper Der Standard features the recent milestones of SCARLETRED in the field of teledermatology. With these, SCARLETRED sets the benchmark for AI-Assisted Screening in telemedicine and radiation oncology.
News
•
Nov 15, 2021
Dermatology & disease management: An interview with an expert about the applications of SCARLETRED
In an interview, specialist Dr. Zikeli discusses the clinical characteristics of atopic dermatitis and why documentation using Scarletred®Vision is an optimal support for diagnosis and progress monitoring.
News
•
Oct 19, 2021
SCARLETRED at the 5th Annual Dermatology Drug Development Summit
The 5th Annual Dermatology Drug Development Summit focusing on development and innovation of therapies and research targeting inflammatory skin diseases, returns to Boston for 2021.
News
•
Oct 15, 2021
Meet SCARLETRED at the 4th Inflammatory Skin Disease Summit
The Inflammatory Skin Disease Summit is a jointly organized event by the Icahn School of Medicine at Mount Sinai and the Austrian Academy of Sciences.
News
•
Sep 27, 2021
The Evolution of SCARLETRED and Artificial Intelligence Assisted Screening in Teledermatology
The clinically validated and award-winning technology, Scarletred®Vision, is on market since 2015, enabling high quality remote skin imaging and objective analysis in over 3000 cutaneous disorders.
News
•
Sep 21, 2021
SCARLETRED at Round-Table Discussion of Börse Express about Life Science Industry in Austria
In the round table discussion of the leading financial domain Börse Express, Marinomed, Scarletred, PHH Rechtsanwälte, and EOSS Industries discussed the development and hurdles of Austrian life science start-ups.
News
•
Jul 27, 2021
SCARLETRED represents Austrian eHealth at the upcoming World EXPO in Dubai
The EXPO 2020 “Connecting Minds, Creating the Future” theme addresses visions of a more networked and technology-based future, covering topics from smart city over sustainability to digital healthcare.
News
•
Nov 26, 2020
Student team winning 3rd place with Scarletred’s challenge on WSA Youth for Innovation program
International team of four talented students has won a 3rd place on WSA Youth for Innovation case study competition by solving Scarletred´s challenge on injection site reactions.
News
•
Sep 1, 2020
Houskapreis 2020: SCARLETRED is nominated for Austria's largest private research award
The research award has been awarded annually by the B&C Private Foundation. With the Houska Prize, the B&C private foundation is committed to improving research conditions and cutting-edge research in Austria.
News
•
May 11, 2020
Stadt Wien zündet den 5G Turbo: 20 Mio. Euro für raschen Ausbau
Wien (OTS) - Videokonferenzen, Home Schooling, Online-Yogastunden – die aktuelle Corona-Situation hat eindrücklich bewiesen, wie wichtig digitale Kommunikation für alle Lebensbereiche geworden ist.
News
•
May 5, 2020
Modern telemedicine for suspected corona cases: SeneCura uses the Scarletred app "eCOVID19"
SeneCura is currently using the CE-certified medical device of Scarletred in eleven care facilities, after which a roll-out to every SeneCura facilities in Austria is planned.
News
•
Mar 13, 2020
Houskapreis 2020: SCARLETRED nominiert für Österreichs größten privaten Forschungspreis
Der Houskapreis ist Österreichs größter privater Forschungspreis. Insgesamt 500.000 Euro vergibt die B&C Privatstiftung für Spitzenforschung aus Österreich.
News
•
Jan 18, 2020
Winner 5G Use Case Challenge
Following a call from the City of Vienna for 5G use case entries in autumn 2019, Azoome and Scarletred, with A1 as their technology partner, have won awards for education and healthcare. Funded pilots will begin this year.
News
•
Jan 12, 2020
Winner of the TechBIZKON III Award in Japan
Last week SCARLETRED won the Japanese TechBIZKON – Digital Health beyond 2020 Award! We want to say thanks to the audience for their strong vote and to EDGEof for making this great digital health event possible.
News
•
Jan 9, 2020
WSA IMPACT STORIES – SCARLETRED
In 2014, while conducting a clinical trial, Dr. Harald Schnidar percieved the need of a technology that allows to objectify dermatological assessments. Reacting to the lack of a suitable solution, he founded SCARLETRED.
News
•
Nov 18, 2019
Ranked in Top-10 of young entrepreneurs in Austria
The GEWINN YOUNG ENTREPRENEUR competition took place for the 30th time, there were about 1,000 first registrations, of which 300 were judged and we are happy to say that SCARLETRED was positioned 7th in the final 100!
Publication
•
September 27, 2021
The mathematics of erythema: Development of machine learning models for artificial intelligence assisted measurement and severity scoring of radiation induced dermatitis
Read more